CBIO
Crescent Biopharma
CBIO
CBIO
87 hedge funds and large institutions have $152M invested in Crescent Biopharma in 2020 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 33 increasing their positions, 21 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
14% more funds holding
Funds holding: 76 → 87 (+11)
0.02% more ownership
Funds ownership: 0.91% → 0.93% (+0.02%)
Holders
87
Holding in Top 10
–
Calls
$475K
Puts
$305K
Top Buyers
| 1 | +$7.1M | |
| 2 | +$1.52M | |
| 3 | +$987K | |
| 4 |
Renaissance Technologies
New York
|
+$970K |
| 5 |
D.E. Shaw & Co
New York
|
+$775K |
Top Sellers
| 1 | -$8.85M | |
| 2 | -$1.88M | |
| 3 | -$1.03M | |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$578K |
| 5 |
Walleye Capital
New York
|
-$541K |